# US 2021/0275552 A1 · SS-lactamase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275552 A1
- Document ID: US20210275552A1
- Status: Published application
- Kind: A1
- Application number: 16/614,052
- Filed: 2018-05-18
- Published: 2021-09-09
- Earliest claimed: 2017-05-18
- Assignees: Oxford University Innovation Limited
- Applicants: Oxford University Innovation Limited
- Inventors: Jürgen BREM; Christopher J. SCHOFIELD; Samuel T. CAHILL; Karina CALVOPINA; Phillip HINCHCLIFFE; Ricky CAIN; James SPENCER; Collin W.G. FISHWICK; Mathew B. AVISON
- Web page: https://patentgrep.com/patent/US20210275552A1

## CPC

- A61K 31/69: Boron compounds
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/431: containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of certain β-lactamase inhibitors in conjunction with one or more β-lactam antibiotics for the treatment of Strenotrophomonas maltophilia, tuberculosis or Pseudomonas species infections.

## Claims

### Claim 1

A combination therapeutic product comprising a β-lactamase inhibitor of Formula I, or a pharmaceutically acceptable salt thereof, and one or more β-lactam antibiotics, wherein the β-lactamase inhibitor of Formula I has the structural formula given below:
wherein:
Q is absent or selected from O, CH2, NH or S;
ring atoms X1, X2, X3, X4 and X5 are either all carbon atoms or one or two of X1, X2, X3, X4 and X5 are nitrogen atoms;
n is 0 or 1;
R1 is a substituent group selected from hydrogen, halo, cyano, nitro, hydroxy or a group of the formula:
—Y—X—Z
wherein
Y is absent or a linker group of the formula —[CRA1RA2]m— in which m is an integer selected from 1 or 2, and RA1 and RA2 are each independently selected from hydrogen or (1-2C)alkyl;
X is absent or —O—, —C(O)—, —C(O)O—, —OC(O)—, —CH(ORA3)—, —N(RA3)—, —N(RA3)—C(O)—, —N(RA3)—C(O)O—, —C(O)—N(RA3)—, —N(RA3)C(O)N(RA3)—, —S—, —SO—, —SO2—, —S(O)2N(RA3)—, or —N(RA3)SO2— wherein RA3 is selected from hydrogen or (1-2C)alkyl; and
Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl or heterocyclyl;
and wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, NRA6RA7, —(CRA4RA5)p—NRA6RA7 (wherein p is selected from 1, 2 or 3), (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-4C)alkanoyl, (1-4C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-2C)alkyl, C(O)NRA6RA7, NRA4C(O)RA5 NRA4S(O)2RA5 and S(O)2NRA4RA5; wherein RA4 and RA5 are each independently selected from hydrogen or (1-4C)alkyl; and wherein RA6 and RA7 are each independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkylamino, (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or RA6 and RA7 can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;
and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z is optionally further substituted by halo, cyano, nitro, hydroxy, caboxy, amino, (1-2C)alkoxy, or (1-2C)alkyl;
R2 is a substituent group selected from hydrogen, halo, cyano, nitro, hydroxy or R2 is selected from:
(i) —C(O)OR2A, wherein R2A is selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C)alkyl, heterocyclyl or heterocyclyl-(1-2C)alkyl, each of which is optionally substituted by one or more substituent groups selected from oxo, halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C)alkoxy, (1-4C)alkyl, or (1-4C)alkanoyl;
(ii) —C(O)NR2BR2C; wherein R2B and R2C are each independently selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C)alkyl, heterocyclyl or heterocyclyl-(1-2C)alkyl, each of which is optionally substituted by one or more substituent selected from oxo, halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C)alkoxy, (1-4C)alkyl, or (1-4C)alkanoyl;
(iii) —C(O)NR2DNR2BR2C; wherein R2D is selected from hydrogen or (1-6C)alkyl and R2B and R2C are as defined above;
(iv) tetrazolyl;
(v) triazolyl;
(vi) —B(OR2F)(OR2G), wherein R2F and R2G are each independently selected from hydrogen, (1-6C)alkyl or R2F and R2G are linked such that, together with the B and O atoms, they form a 5 or 6-membered heterocyclic ring, which is optionally substituted by (1-2C)alkyl; or
(vii) trifluoromethylketone;
R3 is absent or a substituent group selected from halo, cyano, nitro, hydroxy or a group of the formula:
—Y2—X2—Z2
wherein
Y2 is absent or a linker group of the formula [CRC1RC2]n— in which n is an integer selected from 1 or 2, and RC1 and RC2 are each independently selected from hydrogen or (1-2C)alkyl;
X2 is absent or —O—, —C(O)—, —C(O)O—, —OC(O)—, —CH(ORC3)—, —N(RC3)—, —N(RC3)—C(O)—, —N(RC3)—C(O)O, —C(O)—N(RC3)—, —N(RC3)C(O)N(RC3)—, —S—, —SO—, —SO2—, —S(O)2N(RC3)—, or —N(RC3)SO2— wherein RC3 is selected from hydrogen or (1-2C)alkyl; and
Z2 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl or heterocyclyl;
and wherein Z2 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, NRC4RC5, (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-4C)alkanoyl, (1-4C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-2C)alkyl, C(O)NRC4RC5, NRC4C(O)RC5, NRC4S(O)2RC5 and S(O)2NRC4RC5; wherein RC4 and RC5 are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or RC4 and RC5 can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;
and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z2 is optionally further substituted by halo, cyano, nitro, hydroxy, caboxy, NRC6RC7, (1-2C)alkoxy, or (1-2C)alkyl; wherein RC6 and RC7 are selected from hydrogen or (1-2C)alkyl;
with the proviso that when n is O, Q is not absent.
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A combination product according to claim 1, wherein the β-lactamase inhibitor is a compound of Formula I and Q is O.

### Claim 3 (depends on 1)

A combination product according to claim 1, wherein the β-lactamase inhibitor is a compound of Formula I and X4 and X5 are carbon.

### Claim 4 (depends on 1)

A combination product according to claim 1, wherein the β-lactamase inhibitor is a compound of Formula I and R3 is absent or a substituent group selected from halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl or (1-4C)alkanoyl.

### Claim 5 (depends on 1)

A combination product according to claim 1, wherein the β-lactamase inhibitor is a compound of Formula Ib, shown below:
wherein:
X1, X2 and X3 are either all carbon atoms or one of X1, X2 and X3 is a nitrogen atom;
n is 0 or 1;
R1 is a substituent group selected from hydrogen, halo, cyano, nitro, hydroxy or a group of the formula:
—Y—X—Z
wherein
Y is absent or a (1-2C)alkylene;
X is absent or —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(RA3)—, —N(RA3)—C(O)—, —N(RA3)—C(O)O—, —C(O)—N(RA3)—, —N(RA3)C(O)N(RA3)—, —SO2—, —S(O)2N(RA3)—, or —N(RA3)SO2— wherein RA3 is selected from hydrogen or (1-2C)alkyl; and
Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl or heterocyclyl;
and wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, NRA6RA7, —(CRA4RA5)p—NRA6RA7 (wherein p is selected from 1, 2 or 3), (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-4C)alkanoyl, aryl, aryloxy, heterocyclyl, heterocyclyl-(1-2C)alkyl, heteroaryl or heteroaryl-(1-2C)alkyl; wherein RA4 and RA5 are each independently selected from hydrogen or (1-4C)alkyl; and wherein RA6 and RA7 are each independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkyl amino, (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or RA6 and RA7 can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring; and
R2 is a substituent group selected from hydrogen, halo, cyano, nitro, hydroxy or R2 is selected from:
(i) —C(O)OR2A, wherein R2A is selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C)alkyl, heterocyclyl or heterocyclyl-(1-2C)alkyl, each of which is optionally substituted by one or more substituent groups selected from oxo, halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C)alkoxy, (1-4C)alkyl, or (1-4C)alkanoyl; or
(ii) —C(O)NR2BR2C; wherein R2B and R2C are each independently selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C)alkyl, heterocyclyl or heterocyclyl-(1-2C)alkyl, each of which is optionally substituted by one or more substituent selected from oxo, halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C)alkoxy, (1-4C)alkyl, or (1-4C)alkanoyl.

### Claim 6 (depends on 1)

A combination product according to claim 1, wherein the β-lactamase inhibitor is a compound of Formula Ic, shown below:
wherein:
n is 0 or 1;
R1 is a substituent group selected from hydrogen, halo, cyano, nitro, hydroxy or a group of the formula:
—X—Z
wherein
X is —OC(O)—, —N(RA3)—C(O)— or —C(O)—N(RA3)—, wherein RA3 is selected from hydrogen or (1-2C)alkyl; and
Z is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl or heterocyclyl;
and wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, NRA6RA7, —(CRA4RA5)p—NRA6RA7 (wherein p is selected from 1, 2 or 3), (1-4C)alkoxy, (1-4C)alkyl or (1-4C)alkanoyl; wherein RA4 and RA5 are each independently selected from hydrogen or (1-4C)alkyl; and RA6 and RA7 are each independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkylamino, (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or RA6 and RA7 can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;
R2 is a substituent of the formula —C(O)OR2A, wherein R2A is selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C)alkyl, heterocyclyl or heterocyclyl-(1-2C)alkyl, each of which is optionally substituted by one or more substituent groups selected from oxo, halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C)alkoxy, (1-4C)alkyl or (1-4C)alkanoyl.

### Claim 7 (depends on 1)

A combination therapeutic product according to claim 1, wherein the β-lactamase inhibitor is selected from one of the following compounds, or a pharmaceutically acceptable salt thereof:

### Claim 8 (depends on 1)

A combination therapeutic product according to claim 1, wherein the β-lactam antibiotic is selected from one or more of azetreonam, temocillin, piperacillin, cefpodoxime, ceftazidime, cefotaxime, ceftriaxone, meropenem, faropenem, imipenem, loracarbef, ceftobiprole or ceftaroline.

### Claim 9 (depends on 8)

A combination therapeutic product according to claim 8, wherein the one or more β-lactam antibiotic is selected from azetreonam, ceftazidime or meropenem.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a combination therapeutic product according to claim 1, or a compound of Formula I according to claim 1, in association with a pharmaceutically-acceptable excipient or carrier.

### Claim at position 12

12-13. (canceled)

### Claim 14 (depends on 1)

A method for the treatment of a Strenotrophomonas maltophilia, tuberculosis or Pseudomonas infection comprising simultaneously, sequentially or separately administering an effective amount of a combination therapeutic product according to claim 1, or a pharmaceutical composition comprising a combination therapeutic product according to claim 1, or a compound of Formula I according to claim 1, in association with a pharmaceutically-acceptable excipient or carrier.

### Claim 15 (depends on 1)

A method of treating a Strenotrophomonas maltophilia, tuberculosis and/or Pseudomonas infection, the method comprising administering to a patient in need of such treatment a β-lactamase inhibitor of Formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof, in combination with one or more β-lactam antibiotics.

### Claim 16 (depends on 1)

A method of potentiating the effect of a β-lactam antibiotic for the treatment of a Strenotrophomonas maltophilia, tuberculosis and/or Pseudomonas infection, the method comprising the administration of a β-lactamase inhibitor of Formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof, in combination with the β-lactam antibiotic.

### Claim 17 (depends on 1)

A kit of parts comprising the following components:
(i) a β-lactamase inhibitor of Formula I, as defined in claim 1, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier; and
(ii) a β-lactam antibiotic, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier,
wherein the components are provided in a form which is suitable for sequential, separate and/or simultaneous administration.

### Claim 18 (depends on 17)

A kit according to claim 17, for use in the treatment of a Strenotrophomonas maltophilia, tuberculosis and/or Pseudomonas infection.
